News

Cumulative inflammatory burden predicts cancer risk in ulcerative colitis
- Author:
- Bruce Jancin
Second study validates cumulative microscopic inflammation score as independent predictor of colorectal neoplasia.
News

Telerheumatology will thrive post pandemic
- Author:
- Bruce Jancin
Physician-to-physician teleconsults and remote patient monitoring are predicted to be growth areas.
News

Point-Counterpoint: The future of rheumatology is sub-subspecialization
- Author:
- Bruce Jancin
The rheumatology workforce shortage is here and growing.
News

Checkpoint inhibitor–induced rheumatic complications often arise late
- Author:
- Bruce Jancin
Rheumatologic adverse events associated with immune checkpoint inhibitors can happen later in the course of treatment but also can continue after...
News

Evidence grows for food as RA treatment
- Author:
- Bruce Jancin
An enhanced anti-inflammatory diet shows promise for symptom reduction.
News

To improve psoriatic arthritis outcomes, address common comorbidities
- Author:
- Bruce Jancin
Depression and obesity are associated with poor treatment response in PsA.
News

Novel lupus therapies take center stage
- Author:
- Bruce Jancin
Speakers at the 2021 Rheumatology Winter Clinical Symposium spotlighted new drug approvals and new mechanisms of action in SLE, as well as...
News

Recent psoriasis pathophysiology insights carry treatment implications
- Author:
- Bruce Jancin
“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”
News

RA experts highlight key developments over the past year
- Author:
- Bruce Jancin
Highlights include lymphoma risk reduction with biologics, low-dose corticosteroid risk, stratifying VTE risk, treat-to-target strategies and...
News

Rise of JAK inhibitors highlights axial spondyloarthritis year in review
- Author:
- Bruce Jancin
Panelists at the 2021 Rheumatology Winter Clinical Symposium discussed the impact JAK inhibitors will have on the management of patients with...
News

Romosozumab may not increase cardiovascular risk after all
- Author:
- Bruce Jancin
Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box...
News

Consider home subcutaneous immune globulin for refractory dermatomyositis
- Author:
- Bruce Jancin
Patients prefer home subQ over IVIg, citing greater feeling of autonomy.
News
Molecular insights suggest novel therapies for hidradenitis suppurativa
- Author:
- Bruce Jancin
Many key molecular pathways involved in HS pathogenesis can be targeted by commercially available agents having other indications.
News
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b
- Author:
- Bruce Jancin
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
News

Neoadjuvant immunotherapy shows promise in stage III melanoma
- Author:
- Bruce Jancin
There is both preclinical and clinical evidence that neoadjuvant therapy may offer a survival advantage over adjuvant therapy.